These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32292557)

  • 1. Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
    Blomgren P; Chandrasekhar J; Di Paolo JA; Fung W; Geng G; Ip C; Jones R; Kropf JE; Lansdon EB; Lee S; Lo JR; Mitchell SA; Murray B; Pohlmeyer C; Schmitt A; Suekawa-Pirrone K; Wise S; Xiong JM; Xu J; Yu H; Zhao Z; Currie KS
    ACS Med Chem Lett; 2020 Apr; 11(4):506-513. PubMed ID: 32292557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
    Pohlmeyer CW; Shang C; Han P; Cui ZH; Jones RM; Clarke AS; Murray BP; Lopez DA; Newstrom DW; Inzunza MD; Matzkies FG; Currie KS; Di Paolo JA
    BMC Rheumatol; 2021 Mar; 5(1):15. PubMed ID: 33781343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases.
    Tang S; Yu Q; Ding C
    Expert Opin Investig Drugs; 2022 Mar; 31(3):291-303. PubMed ID: 35130124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syk inhibitors in clinical development for hematological malignancies.
    Liu D; Mamorska-Dyga A
    J Hematol Oncol; 2017 Jul; 10(1):145. PubMed ID: 28754125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
    Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
    J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies].
    Ji TT; Chen QN; Tao SD; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):1054-1058. PubMed ID: 32552981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis.
    Káposztás E; Balogh L; Mócsai A; Kemecsei É; Jakus Z; Németh T
    Front Immunol; 2023; 14():1279155. PubMed ID: 38111569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
    Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U
    J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
    Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
    Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.
    Clarke AS; Rousseau E; Wang K; Kim JY; Murray BP; Bannister R; Matzkies F; Currie KS; Di Paolo JA
    Thromb Res; 2018 Oct; 170():109-118. PubMed ID: 30172129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
    Sharman J; Hawkins M; Kolibaba K; Boxer M; Klein L; Wu M; Hu J; Abella S; Yasenchak C
    Blood; 2015 Apr; 125(15):2336-43. PubMed ID: 25696919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
    Ramanathan S; Di Paolo JA; Jin F; Shao L; Sharma S; Robeson M; Kearney BP
    Clin Drug Investig; 2017 Feb; 37(2):195-205. PubMed ID: 27785737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
    Sender S; Sekora A; Villa Perez S; Chabanovska O; Becker A; Ngezahayo A; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Involvement of Syk in pathology of systemic autoimmune disease].
    Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
    Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
    Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
    J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
    Han Y; Ma FY; Di Paolo J; Nikolic-Paterson DJ
    Int J Immunopathol Pharmacol; 2018; 32():2058738418783404. PubMed ID: 29923438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.